Navigation

Aims and Measures

1.    Increase the percentage of patients with CHD or whose 10-year risk is greater than 20% who are on a statin.
 
       Possible measures of accomplishing this aim:
 
       a. Percentage of patients with CHD or whose 10-year risk is greater than 20% who are on statin therapy.
 
       b. Percentage of patients with known CHD or CHD equivalent who are at their LDL goal of less than 100.
 
2. Improve the percentage of patients with or without known CHD who meet their lipid treatment goal.

        Possible measure of accomplishing this aim: 

        a. Percentage of patients with or without known CHD or CHD equivalent who are on lipid-lowering medications who achieve the goal range
                for LDL-cholesterol for their risk group.
 
3. Increase adherence with adjunctive treatment of patients with CHD or CHD equivalent through education.

        Possible measures of accomplishing this aim:

        a. Percentage of patients with CHD or CHD equivalent for whom a diet evaluation has been completed.

        b. Percentage of patients with CHD or CHD equivalent with referral for individual diet instruction or class.

        c. Percentage of patients with CHD or CHD equivalent with documentation of receiving advice about an exercise program.

        d. Percentage of patients with CHD or CHD equivalent who are taking aspirin.
 
4. Improve the percentage of patients on lipid-lowering medication who receive regular follow-up care for lipid disorder.

        Possible measures of accomplishing this aim:
 
        a. Percentage of patients on lipid-lowering medication who have a fasting lipid panel every 3 to 12 months.
 
        b. Of patients on lipid-lowering medications, not achieving LDL goal with visits in the last month, the percentage who received intervention
                (e.g., change in dose, change in treatment, counseling).
 
        c. Of visits in the last month for patients on lipid-lowering medication, not achieving LDL goal, the percentage who received intervention
                (e.g., change in dose, change in treatment, counseling).

5. Increase the percent of patients on lipid-lowering therapy who remain on therapy.

        Possible measures of accomplishing this aim:

        a. Percentage of patients who initiate lipid-lowering therapy who remain on the therapy for 12 months.
 
        b. Percentage of patients who are on lipid-lowering therapy who remain on the therapy in 12-month intervals. 


Measurement Specifications

Possible Success Measure # 3a 


Percentage of patients with diagnosed CHD or CHD equivalent who have had a diet evaluation. 
 
Population Definition 


          All patients age 20 to 75 with diagnosed CHD or CHD equivalent, as defined below 

Data of Interest 

# of patients with CHD or CHD equivalent who have had a diet evaluation


# of patients with diagnosed CHD or equivalent whose records are reviewed 


Numerator/Denominator Definitions 

                Numerator:             Patients with diagnosed CHD or CHD equivalent who have had a diet evaluation.
 
                Denominator:        Patients age 20 to 75 years old with CHD or CHD equivalent include all those who received one or more of the following
                                                ICD-9 codes in the previous 12 months: 410 to 414.9, V45.81 (coronary bypass), or V45.82 (angioplasty). Even if a
                                                patient has never been diagnosed with a lipid disorder, and/or is not on lipid-lowering treatment, they may be included if
                                                they are 20 to 75 years old and have diagnosed heart disease. 

Method/Source of Data Collection 

    The preferred way to collect these data:
 
                        All patients 20 to 75 years old with diagnosed CHD or CHD equivalent could be identified. Each medical group would select at
                         random 20 patients from this list for measurement each month.
 
                        Medical records of these 20 patients would be reviewed to determine if a diet evaluation has been done.
 
    An alternative way to collect the data if automated databases are not available for all patients to be measured:
 
                        All patients 20 to 75 years old with diagnosed CHD or CHD equivalent in the previous 12 months would be identified at the medical
                         group using ICD-9 diagnostic codes from the previous 12 months. Each medical group would select at random 20 patients from this
                         list for measurement each month.
 
                        Medical records of these 20 patients would be reviewed to determine if a diet evaluation has been done. 


Time Frame Pertaining to Data Collection

     Data on 20 patients are collected monthly and reported quarterly.



Possible Success Measure # 4a 

                Percentage of patients on a lipid-lowering medication who have a fasting lipid panel every 3 to 12 months. 


Population Definition 

                All patients age 20 to 75 who are dyslipidemic and on a lipid-lowering medication.
 
Data of Interest 

# of patients on lipid-lowering medication who have a fasting lipid panel 


Total # of patients who are on lipid-lowering medication whose records are reviewed 


Numerator/Denominator Definitions 

               Numerator:             Of the patients in the denominator, those who have had a fasting lipid panel in the past 3 to 12 months (measurement of
                                                total cholesterol, HDL-cholesterol, triglycerides and calculated LDL-cholesterol after a 12-hour fasting period).


    Denominator:          Patients age 20 to 75 years old who are dyslipidemic on a lipid-lowering medication*, including:

                                                    Bile-Acid Sequestrant (BAS)

                                    Fibric Acids

                                    Niacin

                                    Statin

                    * Refer to Appendix C, "Drug Companion Document – Treatment Options for Dyslipidemia," for a complete listing of lipid-lowering medications.



Method/Source of Data Collection

                The preferred way to collect these data:
 
                        Patients 20 to 75 years old who are dyslipidemic and on a lipid-lowering medication could be identified. This would include patients
                         with hypercholesterolemia (high LDL, normal trig and HDL), combined hyperlipidemia (high LDL and trig), hypertriglyceridemia and
                         hypercholesterolemia (with isolated low HDL) who are on a lipid-lowering medication.
 
                        Each medical group would select at random 20 patients for measurement each month to determine if a fasting lipid panel has been
                         done in the past 3 to 12 months. 

Time Frame Pertaining to Data Collection 

                Data on 20 patients are collected monthly and reported quarterly.